Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis – efficacy findings up to week 12
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2020.1747592
Abstract: Abstract Background It is challenging to select the most appropriate biologic treatment for patients with moderate-to-severe plaque psoriasis. Objective To compare speed of onset and level of skin improvement between the interleukin (IL)-17A antagonist ixekizumab… read more here.
Keywords: p19; moderate severe; psoriasis; severe plaque ... See more keywords